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Key points 
 Very few published studies have examined the impact of interventions on 
health-related quality of life (HRQL) for people with dementia, particularly in 
care home settings, despite the global importance of this outcome 
 Antipsychotic review and withdrawal in people with dementia in care homes led 
to detrimental impact on HRQL 
 Social Interaction mitigates the negative impacts of antipsychotic review 
 It is essential to take a judicious approach to antipsychotic withdrawal, and 
prescribers should consider the use of Social Interaction interventions delivered 
by care staff to reduce the risk of harm 
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Background: Very few interventional studies have directly examined the impact of 
treatment approaches on Health-Related Quality of Life (HRQL) in people with 
dementia. This is of particular importance in therapies to address behavioural 
symptoms, where HRQL is often severely affected. 
Methods: Analysis within the WHELD cluster-randomised factorial study in 16 UK care 
homes examining the impact of person-centred care in combination with Antipsychotic 
Review, Social Interaction and Exercise interventions. This study analysed impact on 
HRQL through the DEMQOL-Proxy. 
Results: Data on HRQL were available for 187 participants. People receiving 
Antipsychotic Review showed a significant worsening in two DEMQOL-Proxy domains 
(negative emotion: p=0.02; appearance: p=0.04). A best-case scenario analysis 
showed significant worsening for total DEMQOL proxy score. Social Interaction 
intervention resulted in a significant benefit to HRQL (p=0.04). There was no 
deterioration in HRQL in groups receiving both Antipsychotic Review and Social 
Interaction (p=0.62) 
Conclusions: This demonstrates an important detrimental impact of discontinuation of 
antipsychotics in dementia on HRQL, highlighting the need for careful review of best 
practice guidelines regarding antipsychotic use, and emphasizing the importance of 
providing evidence-based non-pharmacological interventions in conjunction with 
antipsychotic review. 
Introduction 
 
Approximately one third of people with dementia reside in a care home, with up to 80% 
of residents having dementia (Corbett et al., 2013). Although the concept of 
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personhood in dementia suggests that wellbeing and quality of life is achievable for all 
people with dementia given the right environment and person-centred support, most 
studies highlight major impairments in health-related quality of life (HRQL), particularly 
in care home settings. 
 
The combination of cognitive, functional and communication impairment  exerts a 
significant impact on HRQL and frequently leads to prescription of antipsychotic 
medication in these individuals. Meta-analyses of RCTs of atypical antipsychotics in 
people with Alzheimer’s disease (AD) highlight modest benefit in the treatment of 
aggression and psychosis over periods of six to12 weeks (Ballard and Waite, 2006). 
However none of the eighteen RCTs included HRQL as an outcome. This is of 
particular importance because antipsychotics are associated with well-established 
safety concerns, including increased risk of mortality, accelerated cognitive decline, 
stroke, falls and sedation, all of which have the potential to impact negatively on HRQL 
(Ballard et al., 2011, Schneider et al., 2005, Ballard et al., 2009, Schneider et al., 2006, 
Corbett and Ballard, 2012). Secondary analysis from a previous trial of a person-
centred care programme indicated an improvement in HRQL following discontinuation 
of antipsychotic medication (Fossey et al., 2006). More judicious use of antipsychotics 
has been heavily promoted in clinical practice in the past decade, leading to a decline 
in unnecessary prescriptions in the UK (Barnes et al., 2012). Within this changing 
landscape of antipsychotic use there is an urgent need for clarity on the role of 
antipsychotics in practice and their impact on HRQL in people with dementia.  
 
There is increasingly robust evidence supporting the application of Person-centred 
care (PCC) principles and the use of non-pharmacological interventions for the 
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management of neuropsychiatric symptoms. These approaches are prominent in best 
practice guidance (Chenoweth et al., 2009, Fossey et al., 2006, Fossey et al., 2014, 
Teri et al., 1997, Cohen-Mansfield et al., 2007, Moniz Cook et al., 2012). Of note 
however, whilst interventions focussing on PCC training have improved 
neuropsychiatric symptoms (Chenoweth et al., 2009) and reduced antipsychotic 
prescriptions (Fossey et al., 2006), they have not improved HRQL, except in the sub-
group of individuals who discontinued antipsychotics (Fossey et al., 2006). A recent 
systematic review highlighted the benefit of non-pharmacological interventions using 
social interaction and pleasant activities, showing impact on both neuropsychiatric 
symptoms and antipsychotic use (Testad et al., 2014). Studies have also indicated the 
value of physical activity through personalized exercise interventions in improving 
neuropsychiatric symptoms (Teri et al., 2003). A key question is therefore whether 
PCC training approaches can be augmented by specific evidence-based non-
pharmacological interventions. As non-pharmacologcial interventions are the main 
alternative to antipsychotics (Alzheimer's Society, 2012), it is also vital to understand 
the combined impact of antipsychotic review and non-pharmacological treatments to 
inform clincial practice. 
 
There is an emerging consensus of the value in measuring broad patient-rated 
outcomes such as HRQL as well as discrete areas of function like cognition and 
behaviour in people with dementia (Banerjee, 2010, Whitehouse, 2000, Rabins et al., 
2007). The DEMQOL system was developed to generate a robust disease-specific 
measure of HRQL for dementia by using patient self-report and carer proxy report 
(Smith et al., 2007, Smith et al., 2005). DEMQOL-Proxy was developed from a 
conceptual framework that includes health and well-being, cognitive functioning, social 
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relationships, daily activities, and self-concept (Smith et al., 2005). The system was 
developed for use across all types of dementias, care arrangements, and levels of 
severity. Psychometric analysis has shown it to be both reliable and valid. DEMQOL-
Proxy has good psychometric performance in severe dementia as well as mild and 
moderate dementia. 
 
The ‘Improving Wellbeing and Health for People with Dementia’ (WHELD) research 
programme aims to develop and evaluate an optimised antipsychotic review and 
person-centred care (PCC) intervention to reduce antipsychotic use and improve 
wellbeing for people with dementia in care homes. The study adopted a novel factorial 
design to examine the added impact of antipsychotic review, Social Interaction and 
personalized exercise respectively when combined with PCC training. This analysis of 
data from the WHELD RCT therefore sought to determine whether antipsychotic 
review, alone or in combination with evidence-based non-pharmacological 
approaches confers significant benefit to HRQL. The primary outcome of impact on 
neuropsychiatric symptoms is described in a previous publication (Ballard et al., 2016). 
 
Method 
 
Study design 
Analysis of data from a cluster randomised, 2X2X2 factorial design RCT with two 
replications in 16 care homes in the UK in South London, North London, Oxfordshire 
and Buckinghamshire. The unit of randomization was the care home. Each care home 
(cluster) received a randomly allocated intervention for nine months, in addition to 
training in PCC. Most homes were randomized to more than one of the three 
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interventions (antipsychotic review, social intervention, personalised exercise) (Figure 
1). The study received ethical approval from South-Central Oxford REC C 
(11/SC0066). The trial is registered as a clinical trial (ISRCTN Ref: 40313497) and the 
protocol is available online at  
http://www.kcl.ac.uk/ioppn/depts/wolfson/about/people/staff/ballardclive.aspx. 
 
Participants 
This study recruited people with dementia (Stage 1 or greater on the Clinical Dementia 
Rating Scale (Morris, 1993) and/or a score of 4 or greater on Functional Assessment 
Staging (FAST) (Reisberg, 1984)). Care homes had a 2013 Care Quality Commission 
rating of ‘adequate’ or better. Eight homes were selected from a convenience sample 
and another eight were selected randomly. Homes were excluded if less than 60% of 
residents had dementia or if the home was in receipt of local authority special support. 
All eligible residents were invited to participate. Baseline and follow-up data were 
collected on all residents who consented and met the inclusion criteria at each 
participating care home.  
 
Consent for care home involvement was obtained from the care home manager. If 
residents lacked capacity, informed consent was obtained through the involvement of 
a nominated or personal consultee who represented the residents’ interests and 
wishes in accordance with the Mental Capacity Act. Research assistants carried out 
baseline assessments prior to randomisation.  
 
Interventions 
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All 16 homes received a PCC training intervention for nine months. Eight care homes 
were randomised to receive Antipsychotic Review. Eight homes were also randomised 
to Exercise and eight to Social Interaction following the factorial design (Figure 1). The 
interventions were delivered by a trained therapist. Therapists coordinated 
intervention delivery to all homes randomised to that intervention. In each home a 
minimum of two lead staff members (Champions) were trained to implement the 
intervention.  
 
Person-centred care (PCC) 
The PCC intervention was based on tools developed in the evidence-based Focussed 
Intervention for Training of Staff (FITS) manual, which has demonstrated efficacy in a 
RCT (Fossey et al., 2006). Additional evidence-based materials were included to 
provide a comprehensive training and implementation approach. The intervention had 
five main themes: (i) Creating an understanding of dementia and PCC; (ii) Enabling 
each care home to assess how staff deliver PCC; (iii) Recognising the relationship 
between an individuals’ experience, behavior and wellbeing; (iv) Identifying how staff–
resident interactions impact on the care experience; (v) Reviewing care planning and 
delivery based on these PCC principles. This training package was delivered to all 
available staff in participating homes. 
 
Antipsychotic Review  
Antipsychotic Review was based on NICE dementia guidelines and focussed 
specifically on review of antipsychotic prescriptions by primary care physicans or 
psychiatric specialists (National Institute for Health and Clinical Excellence (NICE), 
2006). Review was guided by guidelines on the management of neuropsychiatric 
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symptoms developed by Alzheimer’s Society and the UK Department of Health 
(Alzheimer's Society, 2012). The intervention used the guidelines and additional 
supporting educational resources consistent with international best practice. WHELD 
therapists worked with champions and other staff to develop processes at their care 
home to prompt antipsychotic review. Therapists also worked with physicians and staff 
to augment PCC during antipsychotic withdrawal. The guidelines highlighted the need 
for careful medical assessment of the underlying causes of neuropsychiatric 
symptoms (such as pain and delirium), a first line approach of using non-drug 
interventions, the use of pharmacotherapy only in cases where symptoms were severe 
or causing risk, and the importance of regular review and monitoring of existing 
prescriptions. Care home staff were invited to training sessions focused on the need 
for safe antipsychotic prescribing and review and ways to engage with physicians. 
Physicians attended an interactive seminar and/or practice meeting to discuss the 
guidance and consider specific patient scenarios. The goal of the Antipsychotic 
Review intervention was to promote informed medication review. Prescribing 
decisions were made independently by the participants’ own physician. In the majority 
of cases this was the person’s primary care physician. 
 
Social Interaction with Pleasant Activities 
The Social Interaction intervention was based on three evidence based approaches - 
the Positive Events Schedule (Teri et al., 2008), Social Interaction intervention 
(Cohen-Mansfield et al., 2012) and N.E.S.T programme (Buettner, 2009). with 
supplementary communications skills training for staff to assist in their use of the 
approaches with people with impaired communication. Individualised care plans were 
developed by incorporating information collected about individual’s life histories and 
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interests to ensure that activities were personalised. The Social Interaction 
intervention aimed to provide at least one hour a week of social interaction, or to 
increase social interaction by 20%. 
  
Exercise 
The Exercise intervention was based on two evidence-based protocols, the Seattle 
protocols (Teri et al., 2008) and N.E.S.T manual (Buettner, 2009). The aim was to 
promote physical activity, with a focus on pleasant experience to engage participants 
in at least one hour per week (or 20% more than at baseline). Individual Exercise plans 
were created by the therapist and champion according to the resident’s interests, 
abilities and health status. Exercise plans usually included routine walking with 
additional activities such as seated or standing exercise to music, dancing or chair 
volleyball.  
 
Outcome measures 
HRQL as measured by DEMQOL-Proxy, was a secondary outcome measure in the 
RCT. The instrument consists of 31 items answered on a four point Likert scale (a 
lot/quite a bit/a little/not at all) and administered by an interviewer, blind to treatment 
allocation, using response cards. Items are scored from one to four, generating a total 
score between 31 and 124 with higher scores indicative of better HRQL. All items refer 
to the last week. DEMQOL-Proxy has acceptable content validity and high levels of 
acceptability, reliability, and validity across the range of dementia severity. Further 
exploratory factor analysis carried out in an independent sample (Mulhern et al., 2012, 
Mulhern et al., 2013) derived a five-factor model explaining 49.3% of variance 
(cognition, negative emotion, daily activities, positive emotion, appearance). The main 
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outcome of DEMQOL-Proxy is the total score which yields an assessment of global 
HRQL in dementia. To understand the effects observed, we also completed secondary 
data analyses at a domain level using the five factors identified above.  
  
Antipsychotic and other psychotropic drugs were classified according to the British 
National Formulary. Assessments were carried out at baseline and nine months later 
by research assistants blind to intervention allocation. 
 
Randomisation  
Randomisation was performed as a constrained complete list randomisation stratified 
on the three participating sites. All homes had been recruited before randomisation. 
The constraint ensured an approximately equal distribution of the number of 
interventions to each location. The randomisation system was held at the Bangor 
Clinical Trials Unit (NWORTH) and has been coded and validated in the R statistical 
package (Russell et al., 2011). Selection bias was reduced by inclusion of all 
participants identified as eligible and consented. Homes were approached in the order 
of appearance on the randomised list.  
 
Sample size 
The study was powered to examine reduction in antipsychotic use (Ballard et al., 
2016). HRQL was evaluated as a key exploratory outcome. 
 
Statistical analysis 
The main analysis included age, gender and severity of dementia as covariates. Site 
was also included as a stratification variable. For the evaluation of impact on HRQL, 
12 
 
baseline DEMQOL-proxy score was included as a covariate. For each outcome, a 
model was fitted consisting of the baseline and all three interventions simultaneously 
to reflect the nature of a factorial design. When significant interaction effects were 
identified, these were included in linear models. Throughout, FAST and CDR scores 
were modelled as linear effects as they are naturally ordered. This reduced the degree 
of freedom and increased the statistical power. A p-value of 0.05 was adopted. 
Analyses were conducted using Stata version 13. 
 
The main analyses were treatment as allocated for all individuals with outcome data.  
Sensitivity analyses included an intention-to-treat analysis, imputing data for best and 
worst case scenarios for individuals who died or did not complete follow-up 
assessments. For the main analysis only participants with follow-up data were 
included so the home that withdrew at randomisation was not included.  
 
Results 
 
Cohort characteristics 
Sixteen care homes were recruited and randomised between August and December 
2011, including 277 participants, of whom 195 (70%) completed the study. One home 
withdrew after randomisation but before commencement of the intervention. Outcome 
measures on 12 of 21 participants from this home were collected at nine months. Flow 
of participants through the study is summarised in Figure 2.  
 
Participants had a mean age of 85.3 (SD 7.02) and 74% were female. CDR scores 
were 13% mild, 40% moderate and 47% severe. FAST categories were 11% mild, 6% 
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moderate, 64% moderately severe and 19% severe. 49 participants (18%) were taking 
antipsychotics at baseline, with no significant differences between Antipsychotic 
Review and non-Antipsychotic Review groups. Baseline characteristics are described 
fully in Table 1.  
 
Effect of Antipsychotic Review 
The impact of the Antipsychotic Review on antipsychotic use has been described in a 
parallel report (Ballard et al., 2016). To summarize, the intervention conferred a 
statistically significant 50% reduction in antipsychotic use in the Antipsychotic Review 
group compared to no reduction in the comparison group. There was also a statistically 
significant 30% reduction in mortality in the group receiving Antipsychotic Review and 
Social Interaction (Ballard et al., 2016). 
 
Effect of Antipsychotic Review on HRQL 
DEMQOL-Proxy scores were available for 187 residents at baseline and follow-up. 
Compared to people not receiving Antipsychotic Review, those receiving Antipsychotic 
Review showed a 4.54 (95% CI -9.26 to 0.19) point worsening (p=0.06) in their 
DEMQOL-Proxy scores which approached statistical significance. The worsening in 
HRQL was driven by a statistically significant worsening in the negative emotion (mean 
difference -1.60, 95% CI -2.89 to -0.31); p=0.02) and appearance (mean difference -
0.49; 95% CI -0.94 to -0.04, p=0.04) DEMQOL domains (Table 3). The results were 
similar in sensitivity analyses, but attained statistical significance for a worsening of 
total DEMQOL proxy in the best case scenario analysis (Supplementary Table 1) 
 
Effect of non-pharmacological interventions on HRQL 
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 A statistically significant six-point improvement in HRQL was seen in the group 
receiving Social interaction (Mean difference 6.04, 95% CI 0.24 to 11.84, p=0.04) 
compared to those not receiving this intervention.  
 
Secondary analyses suggested that there were also HRQL improvements observed 
for Social Interaction in the cognition (mean difference 3.07, 95% CI 0.45 to 5.70, 
p=0.03) and appearance (mean difference 0.77; 95% CI 0.22 to 1.32, p=0.01) 
DEMQOL-proxy domains (Table 3). The sensitivity analyses showed similar benefits 
for social intervention on the total DEMQOL proxy, with slightly higher levels of 
statistical significance (Supplementary Table 1). 
 
No impact on overall HRQL (DEMQOL total) was observed for the Exercise 
intervention in the main (Table 3) or sensitivity (Supplementary Table 1) analyses, 
although a significant benefit was seen for positive emotion (Mean difference 1.20, 
95% CI 0.67-1.73, P<0.001) 
 
There were no significant interaction effects between any of the interventions with 
respect to HQRL. However, importantly, there was no deterioration in HQRL in the 
group receiving both Antipsychotic Review and Social Interaction compared to those 
receiving neither of these interventions (mean difference 1.23, 95% CI -3.88 TO 6..33, 
p=0.62), suggesting that reviewing antipsychotics in conjunction with the Social 
Interaction intervention enabled maintenance of HRQL in these individuals. 
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Discussion 
The intervention evaluated in this study, which was designed to be fit-for-purpose for 
UK care homes, focussed on improving the HRQL of people with dementia in these 
settings by implementing best practice and evidence-based guidelines to review 
antipsychotics and utilise psychosocial interventions. The study has two main findings. 
Firstly, that contrary to our hypothesis the rigorous review of antipsychotic medication 
came at a cost in terms of worsening of HRQL by 4.54 points on the DEMQOL-Proxy 
(Cohen’s d effect size 0.32) for those receiving the Antipsychotic Review intervention 
compared to those who did not. Secondly, that Social Interaction, in combination with 
PCC training, resulted in an improvement in HRQL for residents with dementia of 6.04 
points (Cohen’s d -0.51). The effect sizes observed in terms of change in HRQL 
exceed the thresholds that are used to define clinically meaningful benefit, and would 
be defined in established literature as a small to medium effect. They also compare 
favourably with Effect Sizes reported for other interventions with impact on 
HRQL(Cohen, 1988). Importantly however there was no deterioration in HQRL in the 
group receiving concurrent Antipsychotic Review and Social Interaction. 
 
This is the first study to investigate the cost to HQRL of stopping antipsychotics 
through rigorous, evidence-based implementation of antipsychotic review. The 
detrimental impact of Antipsychotic Review on HRQL is an important finding, and had 
not been anticipated. The data generated here are a unique contribution to this debate 
regarding antipsychotic use (Health & Social Care Information Centre, 2012, Barnes 
et al., 2012, Gallini et al., 2014, Centers for Medicare & Medicaid Services, 2013). The 
review protocol used in this study was based on guidance created before the 
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substantial reductions in antipsychotic use that have occurred in the UK over the last 
five years. Whilst this has achieved significant benefits in terms of mortality and other 
adverse effects, it may also mean that the severity of neuropsychiatric symptoms in 
people receiving antipsychotics is likely to be higher than before. A halving of 
prescription rates and a reduction in mortality was achieved in this study (Ballard et 
al., 2016) but it may be that the pressure to discontinue these drugs meant that some 
who were benefiting from them were withdrawn, with a consequent increase in 
neuropsychiatric symptoms and reduction in HRQL (Banerjee et al., 2006). The debate 
on the use of antipsychotics in dementia is one that rapidly becomes polarised. 
However in the absence of other effective pharmacological treatments, these data 
underline the need for care when discontinuing these medications. In particular, the 
results highlight the importance of providing an evidence-based non-pharmacological 
intervention in combination with Antipsychotic Review since this appeared to mitigate 
the negative effects on HRQL. 
 
Previous studies have shown that PCC training can reduce antipsychotics and 
improve neuropsychiatric symptoms, but has not demonstrated an impact on HRQL. 
Importantly, the findings from this study suggest that adding a simple, low intensity 
personalised social intervention to PCC training led to significant benefits in HRQL. 
The addition of enhancement of social interaction, with an emphasis on developing 
care plans provided a concrete and comprehensible framework. This enabled staff to 
understand the principles of PCC and facilitated the integration of PCC into their caring 
role.  
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Improving HRQL, in addition to achieving specific goals or reducing specific symptoms 
or behaviours, should be a key objective of any intervention study in people with 
dementia and is also an essential component for analysing cost-effectiveness. This 
study demonstrates the utility and value of including a measure of HRQL such as 
DEMQOL in evaluations of interventions in complex conditions where success in 
achieving one goal comes at the cost of a decrease in HRQL unless supported by 
other non-pharmacological intervention. 
 
This study has a number of strengths and weaknesses. It represents a robust 
evaluation of a simple and pragmatic enhanced PCC intervention for care homes. The 
study also had excellent retention of surviving participants. The intervention design 
followed best practice guidelines and focussed exclusively on interventions with 
established benefits in improving symptoms in this patient group. It is the first study to 
robustly evaluate a practical care home training intervention in HRQL terms that can 
be easily disseminated and implemented in routine clinical practice. There were also 
limitations. The study was powered as an exploratory study and did not adjust power 
to allow for three main analyses examining impact of interventions on HRQL which 
must be considered in the interpretation of the results. Furthermore, it is important to 
recognise that the DEMQOL-Proxy measure relies on observation of behaviour, 
meaning that behaviour change may lead to a change in score (Hoe et al., 2006). 
However, the results were very consistent across a series of sensitivity analyses. 
 
Conclusion 
This RCT demonstrates an important detrimental impact of discontinuation of 
antipsychotics in dementia on proxy-rated HRQL. The results highlight the need for 
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careful review of best practice guidelines regarding antipsychotic use, and emphasize 
the importance of providing evidence-based non-pharmacological interventions in 
conjunction with antipsychotic review and discontinuation. The study also provides 
clear evidence supporting the value of the WHELD intervention, combining Social 
Interaction with PCC as an effective approach to improve HRQL in people with 
dementia.  
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Table 1 Baseline demographic characteristics of residents by whether or not on 
antipsychotic review. Values are numbers (percentages) or mean (SD) of 
residents, n is the number of non-missing counts in the corresponding 
categories. 
 
 
Characteristic 
Antipsychotic 
review 
Not on 
antipsychotic 
review 
Total 
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 N % N % N % 
Total 146 100 131 100 277 100 
Sex 
Female 110 75.34 95 72.52 205 74.01 
Male 36 24.66 36 27.48 72 25.99 
Ethnicity 
White 132 90.41 115 87.79 247 89.17 
Other 12 8.22 16 12.21 28 10.11 
Missing 2 1.37 0 0.00 2 0.72 
Taking antipsychotics 
On drug 26 17.81 23 17.56 49 17.69 
Not on drug 118 80.82 106 80.92 224 80.87 
Missing 2 1.37 2 1.53 4 1.44 
CDR Score 
Mild 20 13.70 14  10.67 34  12.27 
Moderate 59  40.41 53  40.46 112 40.43 
Severe 67  45.89 64 48.85 131 47.29 
FAST Score 
Mild 19 13.01 11 8.40 30 10.83 
Moderate 8 5.48 8 6.11 16  5.78 
Moderately Severe 93 63.70 84 64.12 177 63.90 
Severe 26 17.81 28  21.27 54 19.49 
 Mean SD Mean SD Mean SD 
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Age at 
assessment 
(years) 
85.28 7.03 85.24 7.04 85.26 7.02 
DEMQOL (proxy)a  105.95 9.29 102.23 14.96 104.21 12.38 
aData missing for three in Antipsychotic Review group and six in non-Antipsychotic 
Review group. *Data missing for one in each intervention group. † Data missing for 
one in each intervention group. N, total number of observations in the 
corresponding category. SD, standard deviation. 
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Table 2: Mean quality of life score (SD) for people with dementia assessed by 
caregivers at baseline and follow up along with the associated mean changes 
(SD) from baseline to follow up and mean (SD) differences between groups for 
completers by interventions 
Quality of life 
score for 
people with 
dementia 
(proxy)  
(n=187) 
Antipsycho
tic Review 
(n=105) 
Not on 
Antipsych
otic 
Review 
 (n=82) 
Social 
Interacti
on 
(n=95) 
Not on 
Social 
Interacti
on(n=92) 
Exercis
e 
(n=91) 
Not on 
Exercis
e 
(n=96) 
Baseline  
106.51  
(9.14) 
102.69 
(15.22) 
105.93 
(12.67) 
103.70 
(11.86) 
106.45 
(11.77) 
103.31 
(12.65) 
Follow up  
102.11  
(13.41) 
105.79 
(10.53) 
106.84 
(8.90) 
100.51 
(14.45) 
103.85 
(12.85) 
103.61 
(11.90) 
Unadjusted 
mean change 
from baseline to 
follow up 
-4.40  
(15.12) 
3.10  
(14.77) 
0.91  
(13.02) 
-3.19 
(17.33) 
-2.60 
(15.74) 
0.30 
(14.99) 
Unadjusted 
mean  difference 
of the mean 
change from 
baseline to follow 
up between the 
-7.5 (21.14) 4.1 (21.68) -2.9 (21.74) 
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two intervention 
groups  
Mean difference 
between the two 
intervention 
groups at follow-
up adjusted 
using linear 
model 
-4.54 (15.06) 6.04 (18.60) -2.66 (18.18) 
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Table 3: Effect estimates for the three interventions for DEMQOL-proxy and the associated 5 sub-scales based on multiple linear 
regression models (complete case analyses)* 
 
 Antipsychotic Review Social Interaction Exercise 
 
Linear 
regressio
n 
Coefficien
t 
 
P 
value 
95% CI 
Linear 
regressio
n 
Coefficien
t 
 
P value 
 
95% CI 
Linear 
regressi
on 
Coefficie
nt 
 
P value 
 
95% CI 
 
DEMQOL-proxy score 
(n=187) 
 
-4.54 (0.059) 
(-9.26 to 
0.19) 
6.04 (0.042) 
(0.24 to 
11.84) 
-2.66 (0.334) 
(-8.34 to 
3.02) 
Cognition sub-score 
(n=183) 
-1.20 (0.284) 
(-3.51 to 
1.10) 
3.07 (0.025) 
(0.45 to 
5.70) 
-1.03 (0.394) 
(-3.54 to 
1.47) 
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Negative emotion sub-
score (n=192) 
-1.60 (0.018) 
(-2.89 to 
-0.31) 
-0.07 (0.924) 
(-1.70 to 
1.55) 
-0.68 (0.378) 
(-2.28 to 
0.92) 
Positive emotion sub-
score (n=189) 
0.14 (0.572) 
(-0.36 to 
0.64) 
0.19 (0.458) 
(-0.35 to 
0.74) 
1.20 
(<0.001
) 
(0.67 to 
1.73) 
Daily activity sub-score 
(n=186) 
-0.44 (0.050) 
(-0.88 to 
0.00) 
0.33 (0.204) 
(-0.20 to 
0.86) 
-0.28 (0.351) 
(-0.89 to 
0.34) 
Appearance sub-score 
(n=188) 
-0.49 (0.035) 
(-0.94 to 
-0.04) 
0.77 (0.009) 
(0.22 to 
1.32) 
-0.30 (0.178) 
(-0.74 to 
0.15) 
*Adjusted for age at baseline assessment, gender, study site, FAST score, CDR score and the corresponding baseline outcome 
measures. Standard errors were adjusted for the clustering effect of care homes. n is the total number of observations used in 
each model. 
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Supplementary Table 1: Sensitivity analyses based on the worst and best case data scenarios as defined for DEMQOL-proxy and 
the associated five sub-scales* 
 Antipsychotic Review Social Interaction Exercise 
 
Linear 
regressio
n 
Coefficien
t 
 
P 
value 
95% CI 
Linear 
regressio
n 
Coefficien
t 
 
P value 
 
95% CI 
Linear 
regressi
on 
Coefficie
nt 
 
P value 
 
95% CI 
Worst Case Scenario 
 
DEMQOL-proxy score 
(n=268) 
 
-5.28 0.124 
-12.19 to 
1.63 
9.93  0.008 
2.95 to 
16.90 
-0.65  0.842 
-7.48 to 
6.18 
Cognition sub-score 
(n=264) 
-1.88  0.280 
-5.47 to 
1.70 
4.89  0.013 
1.20 to 
8.58 
-0.50  0.785 
-4.35 to 
3.34 
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Negative emotion sub-
score (n=272) 
-1.44  0.049 
-2.88 to -
0.006 
0.75  0.302 
-0.74 to 
2.24 
-0.77  0.257 
-2.16 to 
0.62 
Positive emotion sub-
score (n=268) 
0.19 0.338 
-0.21 to 
0.59 
0.42  0.044 
0.01 to 
0.83 
1.13 <0.001 
0.72 to 
1.54 
Daily activity sub-score 
(n=267) 
-0.89  0.137 
-2.10 to 
0.32 
0.65  0.254 
-0.52 to 
1.82 
-0.29  0.567 
-1.33 to 
0.76 
Appearance sub-score 
(n=270) 
-0.51  0.095 
-1.12 to 
0.10 
1.31  0.002 
0.59 to 
2.03 
-0.30  0.364 
-0.98 to 
0.38 
Best Case Scenario 
 
DEMQOL-proxy score 
(n=268) 
 
-4.55  0.048 
-9.05 to -
0.04 
6.09 0.034 
0.54 to 
11.65 
-2.27  0.399 
-7.85 to 
3.31 
Cognition sub-score 
(n=264) 
-1.29  0.234 
-3.52 to 
0.93 
3.00  0.028 
0.38 to 
5.62 
-1.29  0.319 
-3.96 to 
1.38 
28 
 
Negative emotion sub-
score (n=272) 
-1.47  0.021 
-2.68 to -
0.26 
0.002  0.998 
-2.99 to 
0.28 
-0.54  0.437 
-1.98 to 
0.90 
Positive emotion sub-
score (n=268) 
0.10  0.796 
-0.71 to 
0.91 
0.36  0.354 
-0.44 to 
1.16 
1.38  0.004 
0.50 to 
2.25 
Daily activity sub-score 
(n=267) 
-0.44  0.034 
-0.85 to -
0.04 
0.25  0.277 
-0.22 to 
0.71 
-0.28  0.270 
-0.80 to 
0.24 
Appearance sub-score 
(n=270) 
-0.47 0.034 
-0.90 to -
0.04 
0.81 0.008 
0.25 to 
1.37 
-0.37 0.166 
-0.92 to 
0.17 
*Adjusted for age at baseline assessment, gender, study site, FAST score, CDR score and the corresponding baseline outcome 
measures. Standard errors were adjusted for the clustering effect of care homes. n is the total number of observations used in 
each model. 
 
Worst case scenario is the dataset where the DEMQOL Proxy scores for all deaths were imputed as the minimum score in the 
corresponding care homes and for all those lost to follow up or those completed the follow up but with the corresponding outcome 
measures missing were imputed as the mean score in the corresponding care homes. The best case scenario is the dataset where 
the DEMQOL Proxy scores for all deaths were imputed as the mean score in the corresponding care homes and for all those lost to 
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follow up or those completed the follow up but with the corresponding outcome measures missing were imputed as the maximum 
score in the corresponding care homes.  
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